Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Wild type p53 function in p53Y220C mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence

Fig. 5

Wi-A furnished wild type p53 function in mutant p53 (p53Y220C) horboring hepatoma cells. a Viability assay of human hepatocarcinoma with wild type p53 (HuH-6), mutant p53 (HuH-7), and telomerized human cells bearing p53 mutants (p53V143A, p53R249S and p53R273H). b Comparison of response of HuH-6 and HuH-7 cells to Wi-A. Dose response was observed for both the cell lines. HuH-7 showed stronger cytotoxicity to Wi-A. c Western blot showed reduction in mortalin and increase in p53 in cells treated with 1 μM Wi-A in the p53 mutants, p53V143A and p53R273H; p53R249S cells possessed low expression that remained undetected on these blots. In contrast to increase in the expression of p53V143A and p53R273H, mutant p53Y220C protein expression was decreased in Wi-A treated cells. d Dose dependent decrease in mutant p53Y220C protein expression in Wi-A treated cells. e Immunostaining of mortalin and p53 (40 x magnification) in control and Wi-A (0.5 μM) showing increase in nuclear p53V143A and p53R273H. HuH-6 (p53WT) cells showed increase in nuclear p53 staining. In contrast, HuH-7 (p53Y220C) cells exhibited decrease in p53 nuclear staining

Back to article page